Silence Therapeutics - Results of Annual General Meeting

Silence Therapeutics

15/06/2021 17:54

RNS Number : 0091C

Silence Therapeutics PLC

15 June 2021

 

 

 

Results of Annual General Meeting

15 June 2021

 

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announces that at its Annual General Meeting held today, 15 June 2021, all resolutions set out in the notice of meeting were duly passed on a poll.

 

The votes were as follows:

 

Resolution
 *Indicates special resolution
Votes for
%
Votes against
%
Votes total*
% of ISC voted
Votes withheld
1 - Receive and adopt the 2020 UK Annual Report
36,083,741
100.00%
0
0.00%
36,083,741
40.23%
21,958
2 - Re-appoint Mark Rothera as a director
36,030,331
99.79%
74,748
0.21%
36,105,079
40.26%
620
3 - Re-appoint Dr. Michael Davidson as a director
36,080,250
99.93%
24,829
0.07%
36,105,079
40.26%
620
4 - Re-appoint Dr. Giles Campion as a director
36,042,763
99.83%
62,316
0.17%
36,105,079
40.26%
620
5 - Approve the directors' remuneration report
35,285,210
97.73%
820,064
2.27%
36,105,274
40.26%
425
6 - Approve the directors' remuneration policy
35,240,884
97.61%
864,390
2.39%
36,105,274
40.26%
425
7 - Re-appoint PricewaterhouseCoopers LLP as auditors of the Company
27,375,812
97.44%
719,478
2.56%
28,095,290
31.33%
8,010,409
8 - Authorise the directors to allot shares and grant rights to subscribe for, or convert securities into, shares
31,771,639
99.82%
57,480
0.18%
31,829,119
35.49%
4,276,580
9 - Disapply pre-emption rights in connection with an allotment of equity securities for cash*
29,459,251
97.48%
761,703
2.52%
30,220,954
33.70%
5,884,745

 

The number of the Company's ordinary shares in issue as at the date of the meeting was 89,685,448 ordinary shares of nominal value 5p each.

 

*Excludes votes withheld.

A vote withheld is not a vote in law and has not been counted in the calculation of the proportion of votes for and against the resolutions.

 

 

Enquiries:

 

Silence Therapeutics plc
Gem Hopkins, Head of IR & Corporate Communications
Tel: +1 (646) 637-3208
Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
Tel: +44 (0) 20 7597 5970
European PR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
Tel: +44 (0) 20 3709 5700

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
RAGFLFERRFIELIL